• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
CP1
Click for more information
0.00% 17.0¢

CANNPAL ANIMAL THERAPEUTICS LIMITED

Currently unlisted. Proposed listing date: TBA watchlist Created with Sketch. Add to my watchlist

CannPal Animal Therapeutics Limited is an Australia-based pet pharmaceutical company. The... CannPal Animal Therapeutics Limited is an Australia-based pet pharmaceutical company. The Company is focused on research, developing and commercializing therapeutics for the companion animal health industry, using the compounds derived from the cannabis plants. It is focused on cats and dogs. Its lead drug candidate is CPAT-01, which targets osteosarcoma pain in dogs. It is also engaged in investigating and researching the ability to use cannabidiol derived from the hemp plant for developing a nutraceutical range of products for use in companion animals, including dogs, cats, birds, horses and other domestic animals, without a prescription. It is also developing pharmaceutical therapeutics for chronic pain and appetite stimulation. It is developing nutraceutical products for skin conditions, joint health and digestive health.More

Latest Threads

Tag Subject Date Created with Sketch. Comments Created with Sketch. Views Created with Sketch.
CP1
Ann: Implementation of Scheme of Arrangement 		18/03/21 0 704
18/03/21 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  704 
CP1
Ann: Removal from Official List 		18/03/21 0 693
18/03/21 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  693 
CP1
News: CP1 Auscann Says Cannpal Implemented Scheme Of Arrangement 		18/03/21 0 374
18/03/21 Last post  Hot News Comments Created with Sketch.  0  Views Created with Sketch.  374 
CP1
Ann: Implementation of CannPal Scheme of Arrangement 		18/03/21 0 424
18/03/21 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  424 
CP1
Ann: Suspension from Official Quotation 		17/03/21 6 2.9K
17/03/21 Last post  Furiousgeorge Comments Created with Sketch.  6  Views Created with Sketch.  2.9K 
CP1
Creso Pharma (ASX:CPH) eyes medicinal psychedelics market 		15/03/21 0 388
15/03/21 Last post  TheMarketOnline Comments Created with Sketch.  0  Views Created with Sketch.  388 
CP1
Ann: Change of Director's Interest Notice L Mills 		11/03/21 0 555
11/03/21 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  555 
CP1
Ann: Lodgement of Court Orders with ASIC 		11/03/21 0 469
11/03/21 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  469 

See All Discussions arrow Created with Sketch.

Featured News

NEWS Solar building envelope order secured for iconic WA project—discover more about this groundbreaking solar solution
right-arrow Created with Sketch.
NEWS High-grade copper-gold at Mt Isa North—grab samples hit up to 30% Cu and more, with drilling set to begin
right-arrow Created with Sketch.
NEWS Major shallow copper-silver discovery at Junction Prospect confirmed with high-grade intercepts
right-arrow Created with Sketch.
NEWS High-grade antimony mineralization confirmed at Ricciardo with potential 1km strike length
right-arrow Created with Sketch.
NEWS High-grade drilling results extend Cowboy State Mine—172.4m @ 3,716 ppm TREO confirmed
right-arrow Created with Sketch.
NEWS Exceptional rock chip assays at Pearl Copper Project—up to 930 g/t Ag and 10.05% Cu in Arizona
right-arrow Created with Sketch.

Top Stories

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Coda Minerals (ASX:COD) CEO, Chris Stevens, joins The Market Online to discuss the company's current rights issue, and how the capital from this raise will be used to further its copper exploration in South Australia. In addition, Chris talks through the journey the company has taken over the last few years since listing until now.
Canada orders national security review over CGN's 11.26% opposition to Paladin-Fission deal Paladin has disclosed its attempted takeover of Fission Uranium Corp was blocked by a Chinese shareholder late last month.
Firebird achieves preliminary approvals for its Jinshi plant design Firebird Metals Ltd has reached a significant stage in development of its battery-grade manganese sulphate plant in China
Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals Actinogen Medical is developing a promising oral treatment for Alzheimer's and depression and is accelerating clinical trials with new capital.
Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.

Featured News

NEWS High-grade antimony mineralization confirmed at Ricciardo with potential 1km strike length
right-arrow Created with Sketch.
NEWS Shallow high-grade gold hits at Star of Mangaroon and Popeye—see the latest drill results and what’s next
right-arrow Created with Sketch.
NEWS High-grade drilling results extend Cowboy State Mine—172.4m @ 3,716 ppm TREO confirmed
right-arrow Created with Sketch.
NEWS Exceptional rock chip assays at Pearl Copper Project—up to 930 g/t Ag and 10.05% Cu in Arizona
right-arrow Created with Sketch.
NEWS Major shallow copper-silver discovery at Junction Prospect confirmed with high-grade intercepts
right-arrow Created with Sketch.
NEWS Solar building envelope order secured for iconic WA project—discover more about this groundbreaking solar solution
right-arrow Created with Sketch.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.